Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Subsolar-Mass Binaries in the First Half of Advanced LIGO's and Advanced Virgo's Third Observing Run.

Physical review letters·2022
Same author

Point Absorber Limits to Future Gravitational-Wave Detectors.

Physical review letters·2021
Same author

Constraints on Cosmic Strings Using Data from the Third Advanced LIGO-Virgo Observing Run.

Physical review letters·2021
Same author

Approaching the motional ground state of a 10-kg object.

Science (New York, N.Y.)·2021
Same author

Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.

Living reviews in relativity·2020
Same author

GW190521: A Binary Black Hole Merger with a Total Mass of 150  M_{⊙}.

Physical review letters·2020

Related Experiment Video

Updated: Jul 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Iralukast Novartis AG.

A Bramley1

  • 1Pulmonary Research Laboratory, 123-3440 West Broadway, Vancouver, V6R 4R2, Canada. Abramley@prl.pulmonary.ubc.ca

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary

Iralukast, an asthma medication, effectively reduced exercise-induced bronchiospasm in a clinical trial. This leukotriene antagonist shows promise as a well-tolerated treatment for asthma patients.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Trials

Background:

  • Iralukast is an investigational drug developed by Novartis.
  • It functions as a leukotriene D4 (LTD4) and leukotriene E4 (LTE4) antagonist.
  • The drug is currently in Phase II clinical trials for asthma treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of inhaled iralukast in patients with mild to moderate asthma.
  • To assess the impact of iralukast on exercise-induced bronchiospasm.
  • To explore the tolerability of a single inhaled dose of iralukast.

Main Methods:

  • A double-blind, placebo-controlled trial was conducted.
  • 16 patients with mild to moderate asthma participated.
  • A single 1.5 mg inhaled dose of iralukast was administered.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jul 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Main Results:

  • Iralukast significantly reduced the incidence of exercise-induced bronchiospasm.
  • The drug was well-tolerated by the study participants.
  • Novartis is collaborating with Rhone-Poulenc Rorer to utilize the Ultrahaler delivery system for iralukast.

Conclusions:

  • Iralukast demonstrates potential as a therapeutic agent for asthma.
  • Inhaled iralukast is effective in preventing exercise-induced bronchiospasm.
  • Further development and trials are ongoing, including the exploration of related compounds and delivery systems.